ClinicalTrials.gg
RecruitingNCT07207369Updated Nov 24, 2025

A Study to Assess the Safety and Effectiveness of ELAPR002f Injectable Gel in Adult Participants With Atrophic Acne Scars

A Phase 3 interventional study of ELAPR002f Injectable Gel and Saline Control in Acne Scars, sponsored by AbbVie. Recruiting at 10 sites in United States. Open to participants aged 22 Years and older. Per ClinicalTrials.gov, last updated 2025-11-24.

Sponsored by AbbVie · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
395
Allocation
Randomized
Ages
22 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 199 studies in Cicatrix with a site in United States — 25 open to participants now, 35 under way, 2 of them phase 3. Cicatrix · United States.

Planned enrollment
2nd of 185
395 · median 25
Started
2025
with 4 others
Phase 3
3 of 199
1 open now
Primary completion
2029-11
later than 31 of 34 live
Registered
193rd of 199
by date

Among the 199 studies in Cicatrix with a site in United States, this one is the 2nd largest by planned enrollment of the 185 interventional ones that give a count, is one of 5 that started in 2025, is one of 3 in phase 3, reaches primary completion later than 31 of the 34 other live ones, and was the 193rd registered.

Cicatrix

616 studies on the registry are indexed under Cicatrix; 117 are open to participants now.

Browse Cicatrix studies →

Open to participants now

25 of the 199 studies in Cicatrix with a site in United States are open now. Recruiting first, the newest first:

19 more — sign in →

All 25 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 69 Cicatrix studies recruiting now, 34 (49%) set no upper age limit and 31 (45%) stop at 75 or younger; 11 take children under 18; 16 take healthy volunteers.

This study: 22 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 199 studies in Cicatrix with a site in United States, or all of them as a file.
02

Study summary

Atrophic acne scars are flat, indented or with an inverted center scars that develop at the endpoint of the normal healing process for acne. Acne scarring that remains after acne resolves has a significant impact on health related quality of life, including reduced self-esteem and embarrassment/self consciousness. ELAPR002f provides an immediate space-occupying effect for filling in the scar tissue. The purpose of this study is to assess how safe and effective ELAPR002f injectable gel is on adult participants with atrophic acne scars.

ELAPR002f injectable gel is an investigational device being developed for the treatment of facial atrophic acne scars. There are 2 cohorts in this study. In Cohort 1, all participants will receive ELAPR002f injectable gel. In Cohort 2, participants are placed in 1 of 2 groups, called treatment arms. Each group receives a different treatment. There is a 1 in 4 chance that participants will be assigned to the saline active control group. Around 395 adult participants with moderate to severe atrophic acne scarring on both cheeks will be screened in the study in approximately 25 sites in the United States.

Participants will receive 3 treatments over 2 months of intradermal injections of either ELAPR002f injectable gel or saline active control and will be followed for up to an additional 12 months.

There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

03

Conditions studied

  • Acne Scars

Browse trials for

Keywords

  • Acne Scars
  • ELAPR002f injectable gel
04

Who can participate

Ages eligible
22 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants in general good health, and seeking improvement of atrophic acne scars.
  • Moderate to severe atrophic acne scarring (Grade 4 or 5 on the Allergan Acne Scar Improvement Scale [ASIS]) on each cheek based on evaluating investigator (EI) live assessment (both cheeks must qualify but do not need to have the same score) at the first Screening Visit.
  • At least 5 rolling or boxcar-type acne scars in total within the predefined 4 cm × 4 cm assessment field of either cheek in areas of otherwise normal healthy skin, as assessed by the treating investigator (TI).

Exclusion criteria

Exclusion Criteria:

  • The participant has acne on the face.
  • Current cutaneous or mucosal inflammatory or infectious processes other than acne (eg, herpes), rosacea, abscess, an unhealed wound, or a cancerous or precancerous lesion, on the face.
  • The participant presents with predominantly ice pick scars.
  • History of keloid scar formation, hypertrophic scarring, and/or post inflammatory hyperpigmentation or hypopigmentation.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
395 participants (estimated)

Study arms

  • Experimental
    Cohort 1: Open-Label ELAPR002f Injectable Gel

    Participants will receive ELAPR002f Injectable Gel on Days 1, 31, and 61. Participants will be followed for up to 420 days.

    Device: ELAPR002f Injectable Gel

  • Experimental
    Cohort 2: ELAPR002f Injectable Gel

    Participants will receive ELAPR002f Injectable Gel on Days 1, 31, and 61. Participants will be followed for up to 420 days.

    Device: ELAPR002f Injectable Gel

  • Experimental
    Cohort 2: Saline Control

    Participants will receive a saline control on Days 1, 31, and 61. Participants will be followed for up to 420 days.

    Device: Saline Control

Interventions

  • DeviceELAPR002f Injectable Gel

    Intradermal Injections

  • DeviceSaline Control

    Intradermal Injections

06

What researchers measure

Primary outcomes

  1. Percentage of Participants who Achieve a 20% Reduction in Acne Scar Area

    The acne scar area is calculated from 3D camera imaging software. Area is defined as the sum of the individual scar area of the 5 most prominent scars identified by the treating investigator (TI).

    Time frame: Baseline to Day 181

  2. Number of Participants with Adverse Events

    An AE is defined as any untoward medical occurrence in a patient or clinical investigation in which a participant is administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment.

    Time frame: Up to Day 420

  3. Number of Participants with Presence of Binding Antibodies

    Presence of binding antibodies followed by characterization through isotyping and evaluation of cross-reactivity to endogenous tissues.

    Time frame: Up to Day 420

  4. Number of Participants with Injection Site Responses (ISRs) and Systemic Responses

    Incidence of ISRs/systemic responses as recorded by e-diary. ISRs are defined as redness, pain after injection, tenderness to touch, firmness, swelling, lumps/bumps, bruising, itching and discoloration (not redness or bruising).

    Time frame: Up to Day 420

  5. Number of Participants With Clinically Significant Changes From Baseline in Vital Sign Parameters

    Vital sign parameters include body temperature, systolic and diastolic blood pressure, pulse rate, and respiratory rate. The investigator will assess the results for clinical significance.

    Time frame: Up to Day 420

  6. Number of Participants With Clinically Significant Changes From Baseline in Clinical Laboratory Parameters

    Clinical laboratory parameters include tests of hematology, chemistry, and urinalysis. The investigator will assess the results for clinical significance.

    Time frame: Up to Day 420

  7. Number of Participants With Clinically Significant Changes From Baseline in Physical Measurements

    Physical measurements include weight and BMI. The investigator will assess the results for clinical significance.

    Time frame: Up to Day 420

  8. Change from Baseline Procedure Pain

    Participants will assess procedure pain on an 11-point scale ranging from 0 (no pain) to 10 (worst pain imaginable) after each of the 3 treatment sessions.

    Time frame: Up to Day 420

  9. Number of Participants with a Positive Skin Test

    Participants will undergo a skin test in the volar area of the forearm to test for hypersensitivity.

    Time frame: Up to Day 420

  10. Number of Participants with Visual Disturbance Symptoms Associated with Vascular Occlusion

    Number of participants with any acute cognitive changes or any change in confrontational visual fields, ocular motility, or a worsening (1-line change or more) on the Snellen visual acuity assessment.

    Time frame: Up to Day 420

  11. Number of Participants Needing a Histology of Volar Forearm Site Biopsy

    Participants who are suspected of having a hypersensitivity reaction or have a hypersensitivity reaction to the volar forearm injection site will require a punch biopsy of the volar forearm injection site.

    Time frame: Up to Day 420

Secondary outcomes

  1. Change from Baseline on the Overall Score of ACNE-Q Acne Scars Questionnaire

    The ACNE-Q Acne Scars questionnaire includes 10 questions that ask how much the participant is bothered by their acne scars on a 4-point scale ranging from 1=Not at all to 4=Very Much.

    Time frame: Up to Day 420

  2. Change from Baseline on the Overall Score of ACNE-Q - Appearance-Related Distress

    ACNE-Q - Appearance-Related Distress questionnaire includes 8 questions that ask about how the participants describe themselves on a 4-point scale ranging from 1=Never to 4=Always.

    Time frame: Up to Day 420

  3. Change from Baseline on the Overall Score of FACE-Q Satisfaction with Skin Total Score

    FACE-Q Satisfaction With Skin questionnaire includes 12 questions that ask how much the participants are satisfied or dissatisfied with their facial skin on a 4-point scale ranging from 1=Very Dissatisfied to 4=Very Satisfied.

    Time frame: Up to Day 420

  4. Percentage of Participants Achieving "Responder" Status on Either Cheek Based on the Allergan Acne Scar Improvement Scale (ASIS), as assessed by the Evaluating Investigator

    A "responder" is a participant who achieves 1-grade improvement on either cheek based on the ASIS, as assessed by the EI. The ASIS is a 5-grade scale used to assess acne scar improvement ranging from 1=Almost None to 5=Severe. Each side of the face is scored separately.

    Time frame: Up to Day 420

  5. Percentage of Participants who Achieve a 20% Reduction in Acne Scar Area

    The acne scar area is calculated from 3D camera imaging software. Area is defined as the sum of the individual scar area of the 5 most prominent scars identified by the treating investigator (TI).

    Time frame: Up to Day 420

  6. Percent Change from Baseline in Acne Scar Area

    The acne scar area is measured by 3D camera imaging software. Area is defined as the sum of the individual scar area of the 5 most prominent scars identified by the TI.

    Time frame: Up to Day 420

  7. Percent Change from Baseline in Acne Scar Volume

    The acne scar volume is measured by 3D camera imaging software. Volume is defined as the sum of the individual scar volume of the 5 most prominent scars identified by the TI.

    Time frame: Up to Day 420

07

Study locations

10 of 10 sites recruiting
  • Advanced Research Associates - Glendale /ID# 254961
    Glendale, Arizona 85308, United States
    Recruiting
  • Marcus Facial Plastic Surgery /ID# 275880
    Redondo Beach, California 90277, United States
    Recruiting
  • Pacific Clinical Innovations /ID# 256185
    Vista, California 92083-6030, United States
    Recruiting
  • DMR Research PLLC /ID# 256199
    Westport, Connecticut 06880, United States
    Recruiting
  • Hamilton Research, LLC /ID# 256925
    Alpharetta, Georgia 30022, United States
    Recruiting
  • Aesthetic Center at Woodholme /ID# 256197
    Baltimore, Maryland 21208-6391, United States
    Recruiting
  • The Center for Dermatology Cosmetics & Laser Surgery /ID# 256182
    Mount Kisco, New York 10549-3028, United States
    Recruiting
  • Wilmington Dermatology Center /ID# 256192
    Wilmington, North Carolina 28403, United States
    Recruiting
  • Austin Institute for Clinical Research - Pflugerville /ID# 256200
    Pflugerville, Texas 78660, United States
    Recruiting
  • SkinDC /ID# 254962
    Arlington, Virginia 22209, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.

Supporting information: Study protocol, Statistical analysis plan

Time frame: For details on when studies are available for sharing, visit https://vivli.org/ourmember/abbvie/

Access criteria: To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2025 (actual). Primary completion is estimated for Nov 2029, 49 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 2, 2025
First posted
Oct 6, 2025
StartActual
Oct 24, 2025
Primary completionEst.
Nov 2029
CompletionEst.
Nov 2029
Last update
Nov 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07207369
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Oct 6, 2025
Start date
Oct 24, 2025
Primary completion
Nov 2029 (estimated)
Completion
Nov 2029 (estimated)
Last update
Nov 24, 2025

Study contacts

ABBVIE CALL CENTER
Contact
abbvieclinicaltrials@abbvie.com
844-663-3742
ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion